Copper-Based Targeted Nanocatalytic Therapeutics for Non-Small Cell Lung Cancer

• Developed novel hyaluronic acid-modified copper-DMSA nanoparticles (Cu-DMSA-HA NPs) for targeted NSCLC therapy. • HA surface modification enables selective targeting of CD44-overexpressing cancer cells, enhancing uptake and specificity. • NPs deplete glutathione and sustain ROS production via Fenton-like reaction, inducing ferroptosis and suppressing tumor growth. • In vitro and in vivo results demonstrate robust catalytic activity and tumor specificity, highlighting clinical translation potential.